North America Kidney Transplant Market, Size, Share, Growth, Forecast 2023 – 2028 | Renub Research

North America Kidney Transplant Market, Size, Share, Growth, Forecast 2023 – 2028 | Renub Research

May 6, 2024
0 Comments

Renub Research has recently published a report titled “North America Kidney Transplant Market: North America Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” providing a comprehensive analysis of the industry that includes market share insights. In addition, the report comprises competitor and regional research and contemporary extension. North America Kidney Transplant Market is projected to grow with a CAGR of 5.38% over the forecast period (2023-2027).

The North America kidney transplant industry is a dynamic and rapidly evolving sector within the healthcare landscape. With advancements in medical technology, surgical techniques, and immunosuppressive therapies, kidney transplantation has become an established and successful treatment option for end-stage renal disease (ESRD) patients. North America, comprising the United States and Canada, has emerged as a prominent region in the field of kidney transplantation, with a robust infrastructure, well-equipped transplant centers, and a large pool of skilled healthcare professionals. The region also benefits from extensive research and development activities, fostering innovation and improving patient outcomes.  North America Kidney Transplant Market is projected to reach a value of US$ 14.76 Billion by 2027 due to growing demand for kidney transplantation | Renub Research

Request a free sample copy of the report:  https://www.renub.com/request-sample-page.php?gturl=kidney-transplant-market-numbers-and-forecast-for-united-states-mexico-and-canada-302-p.php

Additionally, favorable reimbursement policies, government initiatives, and increased awareness about organ donation have contributed to the growth of the North America kidney transplant industry. As a result, the industry is expected to witness continued growth and advancements in the coming years, providing renewed hope and improved quality of life for ESRD patients.           

In 2022, the United States kidney transplant industry achieved a remarkable milestone with over 25,000 life-saving kidney transplants performed, setting a new record in the region. However, the demand for kidney transplantation continues to outpace the supply of available organs. As of May 2023, the United States alone has 88,753 individuals on the waiting list for a kidney transplant, according to the United Network for Organ Sharing (UNOS). This staggering number highlights the urgent need for increasing organ donations and improving transplant processes. Efforts are underway to raise awareness about organ donation, enhance organ procurement and allocation systems, and promote research and development in the field of kidney transplantation. By addressing these challenges and expanding access to transplantation, the North America kidney transplant industry aims to save more lives and improve the quality of life for patients suffering from end-stage renal disease.

United States has positioned itself as the frontrunner in the kidney transplant industry, leading the market with the highest market share

Renowned for its well-developed healthcare system, advanced medical facilities, and robust infrastructure, the country has become a preferred destination for individuals seeking kidney transplantation. With top-tier transplant centres and highly skilled healthcare professionals specializing in successful kidney transplant procedures, the United States offers exceptional expertise in the field.

Moreover, the country’s continuous progress in immunosuppressive therapies, surgical techniques, and organ procurement processes has further solidified its dominant market position. The substantial market share of the United States in the kidney transplant industry demonstrates its unwavering commitment to delivering quality healthcare services and driving improved outcomes for patients with end-stage renal disease.

Region – Kidney Transplant Market breakup from 3 Regions:

1.    United States

2.    Canada

3.    Mexico

Living Donor Transplant market is on track to witness significant growth in the foreseeable future

Living donor transplantation offers numerous advantages, including superior outcomes, reduced waiting times, and improved graft survival rates when compared to deceased donor transplantation. These compelling benefits, coupled with the increasing awareness and acceptance of living donor transplantation, are serving as key drivers for market expansion. Furthermore, continuous advancements in surgical techniques, immunosuppressive therapies, and organ preservation methods have substantially enhanced the success rates of living donor transplants, further augmenting the market’s growth trajectory. The rising demand for organs, coupled with the persistent shortage of deceased donor organs, has underscored the importance of living donor transplantation as a viable solution. Consequently, the Living Donor Transplant market is projected to experience remarkable growth in the coming years, bringing immense benefits to patients in the need of organ transplantation and contributing to the advancement of the broader healthcare industry.

Type – Kidney Transplant Market breakup from 2 viewpoints:

1.    Deceased Donor Transplant

2.    Living Donor Transplant

Calcineurin inhibitors are a vital class of immunosuppressive drugs widely employed in North America kidney transplant market

The Calcineurin Inhibitors market is experiencing significant growth driven by advancements in technology and healthcare. These inhibitors play a crucial role in immunosuppressive therapy for organ transplantation and autoimmune disorders. Research and development efforts have led to improved formulation, delivery, and effectiveness of these inhibitors. Innovations in drug delivery systems and bioavailability have increased demand. Factors such as the rising rates of organ transplantation, incidence of autoimmune diseases, and aging population contribute to market growth. The integration of digital healthcare solutions like telemedicine and remote monitoring has further accelerated the adoption of calcineurin inhibitors.

Drugs – Kidney Transplant Market breakup from 4 viewpoints

1.    Calcineurin inhibitors

2.    Antiproliferative agents

3.    mTor inhibitor

4.    Steroids

5.    Antibodies

About the Company: 

Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

Contact Us:

Renub Research         

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Email: info@renub.com

LinkedIn: https://in.linkedin.com/company/renub-research

Web: www.renub.com

Add a comment

Your email address will not be published. Required fields are marked *

益生菌對人體的益處

Boo
December 25, 2024
吃不下、排不出、消化不好……都會被安利一波 “益生菌”,似乎 “益生菌” 治百病似的,而且不僅給孩子吃,大人們自己也是頻頻種草。 拉肚子了怎麽辦?——吃益生菌! 便秘了怎麽辦?——吃益生菌! 消化不良怎麽辦?——吃益生菌! 腸脹氣怎麽辦?——吃益生菌! 不愛吃飯怎麽辦?——吃益生菌! 那麽更深層次的疑問也就隨之而來:益生菌,真有這麽神嗎?日本表飛鳴益生菌,是越多越好嗎?益生菌,真的無所不能嗎?喝下去的益生菌一定會起作用嗎?河北農業大學食品科技學院高潔將爲你一一解開迷惑。 益生菌到底是什麽? 益生菌的英文名叫 Probiotic,來源于希臘語,本意是 “對生命有益”,所以顧名思義,益生菌就是對生命有益的菌,是一種通過改善人體微生物平衡從而對宿主施加有益影響的微生物,主要是細菌。 我們正常人體內,以腸道爲主,存在大量的共生菌群,超過1000萬億個,益生菌這類細菌不但不是致病菌,反而能通過改善腸道微生物的平衡,産生不可替代的生理作用。 爲了讓大家吃得放心,我國設計了一個嚴格的評審系統來給它們做身份認證,通過了的才是有名分、能作爲商品流通的益生菌。它們分別是兩岐雙岐杆菌、嬰兒雙岐杆菌、長雙岐杆菌、短雙岐杆菌、青春雙岐杆菌、德氏乳杆菌保加利亞種、嗜酸乳杆菌、幹酪乳杆菌幹酪亞種、嗜熱鏈球菌、羅伊氏乳杆菌。另外還有一組比較特殊的,叫 “可用于嬰幼兒食品的菌種”,包括嗜酸乳杆菌、動物雙歧杆菌、乳雙歧杆菌、鼠李糖乳杆菌,也屬于有名分的益生菌。 平時醫院、藥店裏所購買的一般都是益生菌制劑,益生菌制劑和益生菌不同,益生菌制劑是一種由益生菌加工而成的産品,它除了含有益生菌成分外,可能還含有食用香精、乙醇、甜菊素、麥芽糊精等等一些添加劑成分,雖然這些添加劑經國家安全認證,但不表示此類制劑可以長期服用。...
QAS Autos is a multi service company that was established in 2019 in New York. We provide the inventory, parts and service under one roof. We also provide shipping, container loading, half and full cut of vehicles.
Copyright © 2021. All rights reserved.